Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review

Moufarrij, Sara; Sassine, Dib; Başaran, Derman; Jewell, Elizabeth L.

doi:10.1016/j.ygyno.2023.01.012

Cited by 6 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain malignancies and anticancer therapies are associated with an increased risk of venous thromboembolism ( Moufarrij et al, 2023 , Khorana et al, 2013 ); however, romiplostim does not appear to significantly increase such a risk ( Rodeghiero et al, 2013 ). In our study, only one patient reported an adverse event due to romiplostim (deep vein thrombosis) during the first 60 days of administration.…”

Section: Discussionmentioning

confidence: 99%

Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers

Moufarrij,

O'Cearbhaill,

Zhou

et al. 2024

Gynecologic Oncology Reports

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers

Moufarrij,

O'Cearbhaill,

Zhou

et al. 2024

Gynecologic Oncology Reports

Self Cite

View full text Add to dashboard Cite

“…Thus, it seems that Khorana’s model is an unreliable tool for predicting VTE events in this high-risk population. Given the high incidence of VTE in this subset of ovarian cancer patients, future research should consider a new risk stratification to identify ovarian cancer patients at risk of thrombosis during neoadjuvant chemotherapy [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Venous Thromboembolism Prophylaxis in Gynecologic Oncology: A MITO-MaNGO Survey

Mongelli,

Lorusso,

Zanagnolo

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Cancer-associated thrombosis is the second leading cause of death in cancer patients, and its incidence has been increasing in recent years. This survey was aimed at gathering information regarding the management of thromboembolic prophylaxis within the MITO (Multicenter Italian Trials in Ovarian Cancer)-MaNGO (Mario Negri Gynecologic Oncology) groups. We designed a self-administered, multiple-choice online questionnaire available only for MITO-MaNGO members for one month, starting in May 2022 and ending in June 2022. We processed one response form per center, and 50 responses were analyzed, with most of the respondents (78%) over 40 years old. We found that 82% of them consider thromboembolic prophylaxis in gynecologic oncology to be relevant. In 82% of the centers, a standardized protocol on venous thromboembolism (VTE) prophylaxis is used, which is applied to both patients undergoing surgery and those undergoing chemotherapy. In the remaining 18% of centers, prophylaxis is used exclusively for patients undergoing chemotherapy treatment. Prophylaxis of patients undergoing surgery and chemotherapy treatment is managed in most cases by the surgeon (72%) and oncologist (76%), respectively. Only 26% of respondents use a thromboembolic risk assessment scale, and of these, those used are the Caprini Score (6%), Khorana Score (6%), and Wells Score (2%). The respondents have good knowledge of low-molecular-weight heparin (90%) and average knowledge of dicumarolics (40%), direct oral anticoagulants (DOACs) (68%), and antiplatelet agents (40%). The results of our survey indicate that there is a good awareness of thromboembolic prophylaxis in gynecologic oncology. Nevertheless, it is used less in outpatients than in patients undergoing surgery. Moreover, the thromboembolic risk assessment scores are barely used.

show abstract

Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?

Shafa

Watkins

McGree

et al. 2023

Gynecologic Oncology

View full text Add to dashboard Cite

Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review

Cited by 6 publications

References 30 publications

Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers

Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers

Venous Thromboembolism Prophylaxis in Gynecologic Oncology: A MITO-MaNGO Survey

Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?

Contact Info

Product

Resources

About